JPWO2020198478A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020198478A5 JPWO2020198478A5 JP2021557368A JP2021557368A JPWO2020198478A5 JP WO2020198478 A5 JPWO2020198478 A5 JP WO2020198478A5 JP 2021557368 A JP2021557368 A JP 2021557368A JP 2021557368 A JP2021557368 A JP 2021557368A JP WO2020198478 A5 JPWO2020198478 A5 JP WO2020198478A5
- Authority
- JP
- Japan
- Prior art keywords
- methanone
- imidazol
- piperidin
- phenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 16
- -1 4-(1H-imidazol-2-yl)piperidin-1-yl Chemical group 0.000 claims 15
- IHTMWFOCBBHMKY-UHFFFAOYSA-N N1C=C(C2=CC=CC=C12)C1=CC=C(C=C1)C(=O)N1CCC(CC1)C=1NC(=CN=1)C Chemical compound N1C=C(C2=CC=CC=C12)C1=CC=C(C=C1)C(=O)N1CCC(CC1)C=1NC(=CN=1)C IHTMWFOCBBHMKY-UHFFFAOYSA-N 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- NQQYOMFKNHOZNF-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)F Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)F NQQYOMFKNHOZNF-UHFFFAOYSA-N 0.000 claims 11
- VXPVHTYTXOABTN-UHFFFAOYSA-N N1N=C(C2=CC=CC=C12)C1=CC=C(C=C1)C(=O)N1CCC(CC1)C=1NC(=CN=1)C Chemical compound N1N=C(C2=CC=CC=C12)C1=CC=C(C=C1)C(=O)N1CCC(CC1)C=1NC(=CN=1)C VXPVHTYTXOABTN-UHFFFAOYSA-N 0.000 claims 11
- NISWUCTZHOVAKY-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=CC=2OCOC=21 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=CC=2OCOC=21 NISWUCTZHOVAKY-UHFFFAOYSA-N 0.000 claims 9
- QGHVQRWIOGVIHC-UHFFFAOYSA-N N1C(=NC=C1)NC1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)F Chemical compound N1C(=NC=C1)NC1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)F QGHVQRWIOGVIHC-UHFFFAOYSA-N 0.000 claims 9
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 8
- HOOQBEDJEBSPJR-UHFFFAOYSA-N CC1=CN=C(N1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F Chemical compound CC1=CN=C(N1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F HOOQBEDJEBSPJR-UHFFFAOYSA-N 0.000 claims 7
- CVKWRHLQTPBJPT-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F CVKWRHLQTPBJPT-UHFFFAOYSA-N 0.000 claims 7
- IWWDBOKOYCHXDJ-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CNC2=CC=CC=C12 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CNC2=CC=CC=C12 IWWDBOKOYCHXDJ-UHFFFAOYSA-N 0.000 claims 7
- HXUHKQYUEWKJDW-UHFFFAOYSA-N N1C(=NC=C1)CC1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)F Chemical compound N1C(=NC=C1)CC1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)F HXUHKQYUEWKJDW-UHFFFAOYSA-N 0.000 claims 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- ONQBDOKSBNMEJL-UHFFFAOYSA-N CC1=CN=C(N1)C1CCN(CC1)C(=O)C1=CC=C2C(=CNC2=C1)C1=CC=CC=C1 Chemical compound CC1=CN=C(N1)C1CCN(CC1)C(=O)C1=CC=C2C(=CNC2=C1)C1=CC=CC=C1 ONQBDOKSBNMEJL-UHFFFAOYSA-N 0.000 claims 4
- KIUPDWSCXGPDEW-UHFFFAOYSA-N CC=1N=C(NC=1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=C(NC2=CC=CC=C12)C Chemical compound CC=1N=C(NC=1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=C(NC2=CC=CC=C12)C KIUPDWSCXGPDEW-UHFFFAOYSA-N 0.000 claims 4
- WNHRWYSYNAVSII-UHFFFAOYSA-N FC=1C=C2C(=CNC2=CC=1)C1=CC=C(C=C1)C(=O)N1CCC(CC1)C=1NC=C(N=1)C Chemical compound FC=1C=C2C(=CNC2=CC=1)C1=CC=C(C=C1)C(=O)N1CCC(CC1)C=1NC=C(N=1)C WNHRWYSYNAVSII-UHFFFAOYSA-N 0.000 claims 4
- GYPIWPLSJFVFST-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=2NC3=CC=CC=C3C=2C=C1 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=2NC3=CC=CC=C3C=2C=C1 GYPIWPLSJFVFST-UHFFFAOYSA-N 0.000 claims 4
- BINUCYUHBKPPOF-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=C2C=CNC2=CC=C1 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=C2C=CNC2=CC=C1 BINUCYUHBKPPOF-UHFFFAOYSA-N 0.000 claims 4
- LDJDEWSPJQNXIM-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC(=CC=C1)Cl Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC(=CC=C1)Cl LDJDEWSPJQNXIM-UHFFFAOYSA-N 0.000 claims 4
- VVPCNOCTMILBED-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)C Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC(=CC=C1)S(=O)(=O)C VVPCNOCTMILBED-UHFFFAOYSA-N 0.000 claims 4
- MLFDJTIZOQONEZ-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC2=C(OCO2)C=C1 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC2=C(OCO2)C=C1 MLFDJTIZOQONEZ-UHFFFAOYSA-N 0.000 claims 4
- KDWOFBGJWADZMH-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=NNC2=CC=CC=C12 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=NNC2=CC=CC=C12 KDWOFBGJWADZMH-UHFFFAOYSA-N 0.000 claims 4
- ANMYTJGAQVRFNE-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C=1NC2=CC=CC=C2C=1 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C=1NC2=CC=CC=C2C=1 ANMYTJGAQVRFNE-UHFFFAOYSA-N 0.000 claims 4
- MSQZSLQPCWNUAQ-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C=1SC(=CC=1)C(F)(F)F Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C=1SC(=CC=1)C(F)(F)F MSQZSLQPCWNUAQ-UHFFFAOYSA-N 0.000 claims 4
- LXZGWKLKDNXLOO-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)N1C=CC2=CC=CC=C12 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)N1C=CC2=CC=CC=C12 LXZGWKLKDNXLOO-UHFFFAOYSA-N 0.000 claims 4
- DCSHGSOHOCAWKN-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)NC1=CC=CC=C1 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)NC1=CC=CC=C1 DCSHGSOHOCAWKN-UHFFFAOYSA-N 0.000 claims 4
- JYYXAHJWGKJBEA-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)OC1=CC=CC=C1 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)OC1=CC=CC=C1 JYYXAHJWGKJBEA-UHFFFAOYSA-N 0.000 claims 4
- MKLFGDJYMIDGFM-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C2C(=CNC2=C1)C1=CC=CC=C1 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C2C(=CNC2=C1)C1=CC=CC=C1 MKLFGDJYMIDGFM-UHFFFAOYSA-N 0.000 claims 4
- ZMVXMMMUQJGCPT-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C2C(=CNC2=C1)C1=CNC2=CC=CC=C12 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C2C(=CNC2=C1)C1=CNC2=CC=CC=C12 ZMVXMMMUQJGCPT-UHFFFAOYSA-N 0.000 claims 4
- YXGQQEJTOCWVND-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C=1C=C2C=CN(C2=CC=1)C1=CC=CC=C1 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C=1C=C2C=CN(C2=CC=1)C1=CC=CC=C1 YXGQQEJTOCWVND-UHFFFAOYSA-N 0.000 claims 4
- OINPDRWMJVCLKT-UHFFFAOYSA-N N1C(=NC=C1)C1CCN(CC1)C(=O)C=1C=CC2=C(OC3=C2C=CC=C3)C=1 Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C=1C=CC2=C(OC3=C2C=CC=C3)C=1 OINPDRWMJVCLKT-UHFFFAOYSA-N 0.000 claims 4
- VSKBHHBIRNYFPS-UHFFFAOYSA-N N1C(=NC=C1)CC1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F Chemical compound N1C(=NC=C1)CC1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F VSKBHHBIRNYFPS-UHFFFAOYSA-N 0.000 claims 4
- GXJOYETXYQAFMX-UHFFFAOYSA-N N1C(=NC=C1)NC1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F Chemical compound N1C(=NC=C1)NC1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F GXJOYETXYQAFMX-UHFFFAOYSA-N 0.000 claims 4
- GRAJBUXLYMPAHB-UHFFFAOYSA-N N1C(=NC=C1)NC1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)F Chemical compound N1C(=NC=C1)NC1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C(F)F GRAJBUXLYMPAHB-UHFFFAOYSA-N 0.000 claims 4
- MQHRBQYFRJASIT-UHFFFAOYSA-N N1C=CC2=CC=C(C=C12)C1=CC=C(C=C1)C(=O)N1CCC(CC1)C=1NC(=CN=1)C Chemical compound N1C=CC2=CC=C(C=C12)C1=CC=C(C=C1)C(=O)N1CCC(CC1)C=1NC(=CN=1)C MQHRBQYFRJASIT-UHFFFAOYSA-N 0.000 claims 4
- SYQSMBDGLVEXNY-UHFFFAOYSA-N [4-(1H-imidazol-2-yl)piperidin-1-yl]-[4-[3-(trifluoromethyl)phenyl]phenyl]methanone Chemical compound N1C(=NC=C1)C1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=CC(=CC=C1)C(F)(F)F SYQSMBDGLVEXNY-UHFFFAOYSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Claims (15)
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3’-(メチルスルホニル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-インドール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-インダゾール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-((1H-イミダゾール-2-イル)アミノ)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-フェノキシフェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(フェニルアミノ)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3’-クロロ-[1,1’-ビフェニル]-4-イル)メタノン、トリフルオロ酢酸塩、
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、トリフルオロ酢酸塩、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-5-イル)フェニル)メタノン、トリフルオロ酢酸塩、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(9H-カルバゾール-2-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(ジベンゾ[b,d]フラン-3-イル)メタノン、トリフルオロ酢酸塩、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-4-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-1-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-4-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(1-フェニル-1H-インドール-5-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(5-(トリフルオロメチル)チオフェン-2-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-3-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インダゾール-3-イル)フェニル)メタノン、
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(4-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(2-メチル-1H-インドール-3-イル)フェニル)メタノン、
(4-(1H-インドール-6-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(1H,1’H-[3,4’-ビインドール]-6-イル)メタノン、
[4-(1H-イミダゾール-2-イル)-1-ピペリジル]-[3-(1H-インドール-3-イル)-1H-インドール-6-イル]メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-2-イル)フェニル)メタノン、
(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(3-フェニル-1H-インドール-6-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3-フェニル-1H-インドール-6-イル)メタノン、
(4-((1H-イミダゾール-2-イル)アミノ)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、および
(4-(5-フルオロ-1H-インドール-3-イル)フェニル)(4-(4-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、ならびにそれらの獣医学的に許容される塩からなる群から選択される、化合物。 (4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-fluoro-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-indol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-indazol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-phenoxyphenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(phenylamino)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-chloro-[1,1′-biphenyl]-4-yl)methanone, trifluoroacetate,
(4-((1H-imidazol-2-yl)methyl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, trifluoroacetate ,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-5-yl)phenyl)methanone, trifluoroacetate,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(9H-carbazol-2-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(dibenzo[b,d]furan-3-yl)methanone, trifluoroacetate,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-4-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-1-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-4-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(1-phenyl-1H-indol-5-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(5-(trifluoromethyl)thiophen-2-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-3-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indazol-3-yl)phenyl)methanone,
(4-((1H-imidazol-2-yl)methyl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(4-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4-(2-methyl-1H-indol-3-yl)phenyl)methanone,
(4-(1H-indol-6-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(1H,1′H-[3,4′-vindol]-6-yl)methanone,
[4-(1H-imidazol-2-yl)-1-piperidyl]-[3-(1H-indol-3-yl)-1H-indol-6-yl]methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-2-yl)phenyl)methanone,
(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)(3-phenyl-1H-indol-6-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3-phenyl-1H-indol-6-yl)methanone,
(4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and (4-( 5-fluoro-1H-indol-3-yl)phenyl)(4-(4-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone, and veterinary acceptable salts thereof A compound selected from the group consisting of
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-インドール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-インダゾール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-4-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-3-イル)フェニル)メタノン、
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、および
(4-(4-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(2-メチル-1H-インドール-3-イル)フェニル)メタノン、ならびにそれらの獣医学的に許容される塩からなる群から選択される、請求項1に記載の化合物。 (4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-fluoro-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-indol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-indazol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-4-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-3-yl)phenyl)methanone,
(4-((1H-imidazol-2-yl)methyl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and (4-( from 4-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4-(2-methyl-1H-indol-3-yl)phenyl)methanone, and veterinary acceptable salts thereof 2. The compound of claim 1, selected from the group consisting of:
(4-(1H-インドール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-インダゾール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-4-イル)フェニル)メタノン、および
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、ならびにそれらの獣医学的に許容される塩からなる群から選択される、請求項2に記載の化合物。 (4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-fluoro-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-indol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-indazol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-4-yl)phenyl)methanone, and (4-((1H-imidazole) -2-yl)methyl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and veterinary acceptable salts thereof 3. A compound according to claim 2, selected from the group.
(4-(1H-インダゾール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、および
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、ならびにそれらの獣医学的に許容される塩からなる群から選択される、請求項3に記載の化合物。 (4-(1H-indol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-indazol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and (4-((1H- from imidazol-2-yl)methyl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and veterinary acceptable salts thereof 4. The compound of claim 3, selected from the group consisting of:
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3’-(メチルスルホニル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-インドール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-インダゾール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-((1H-イミダゾール-2-イル)アミノ)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-フェノキシフェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(フェニルアミノ)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3’-クロロ-[1,1’-ビフェニル]-4-イル)メタノン、トリフルオロ酢酸塩、
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、トリフルオロ酢酸塩、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-5-イル)フェニル)メタノン、トリフルオロ酢酸塩、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(9H-カルバゾール-2-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(ジベンゾ[b,d]フラン-3-イル)メタノン、トリフルオロ酢酸塩、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-4-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-1-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-4-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(1-フェニル-1H-インドール-5-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(5-(トリフルオロメチル)チオフェン-2-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-3-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インダゾール-3-イル)フェニル)メタノン、
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(4-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(2-メチル-1H-インドール-3-イル)フェニル)メタノン、
(4-(1H-インドール-6-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(1H,1’H-[3,4’-ビインドール]-6-イル)メタノン、
[4-(1H-イミダゾール-2-イル)-1-ピペリジル]-[3-(1H-インドール-3-イル)-1H-インドール-6-イル]メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-2-イル)フェニル)メタノン、
(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(3-フェニル-1H-インドール-6-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3-フェニル-1H-インドール-6-イル)メタノン、
(4-((1H-イミダゾール-2-イル)アミノ)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、および
(4-(5-フルオロ-1H-インドール-3-イル)フェニル)(4-(4-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、ならびにそれらの獣医学的に許容される塩からなる群から選択される化合物を含む、組成物。 (4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-fluoro-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-indol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-indazol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-phenoxyphenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(phenylamino)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-chloro-[1,1′-biphenyl]-4-yl)methanone, trifluoroacetate,
(4-((1H-imidazol-2-yl)methyl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, trifluoroacetate ,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-5-yl)phenyl)methanone, trifluoroacetate,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(9H-carbazol-2-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(dibenzo[b,d]furan-3-yl)methanone, trifluoroacetate,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-4-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-1-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-4-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(1-phenyl-1H-indol-5-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(5-(trifluoromethyl)thiophen-2-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-3-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indazol-3-yl)phenyl)methanone,
(4-((1H-imidazol-2-yl)methyl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(4-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4-(2-methyl-1H-indol-3-yl)phenyl)methanone,
(4-(1H-indol-6-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(1H,1′H-[3,4′-vindol]-6-yl)methanone,
[4-(1H-imidazol-2-yl)-1-piperidyl]-[3-(1H-indol-3-yl)-1H-indol-6-yl]methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-2-yl)phenyl)methanone,
(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)(3-phenyl-1H-indol-6-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3-phenyl-1H-indol-6-yl)methanone,
(4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and (4-( 5-fluoro-1H-indol-3-yl)phenyl)(4-(4-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone, and veterinary acceptable salts thereof A composition comprising a compound selected from the group consisting of
(4-(1H-インドール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-インダゾール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-4-イル)フェニル)メタノン、および
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、ならびにそれらの獣医学的に許容される塩からなる群から選択される化合物を含む、請求項6に記載の組成物。 (4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-fluoro-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-indol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-indazol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-4-yl)phenyl)methanone, and (4-((1H-imidazole) -2-yl)methyl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and veterinary acceptable salts thereof 7. The composition of claim 6, comprising a compound selected from the group.
(4-((1H-イミダゾール-2-イル)アミノ)ピペリジン-1-イル)(4’-フルオロ-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3’-(メチルスルホニル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-インドール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-インダゾール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-((1H-イミダゾール-2-イル)アミノ)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-フェノキシフェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(フェニルアミノ)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3’-クロロ-[1,1’-ビフェニル]-4-イル)メタノン、トリフルオロ酢酸塩、
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、トリフルオロ酢酸塩、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-5-イル)フェニル)メタノン、トリフルオロ酢酸塩、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(9H-カルバゾール-2-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(ジベンゾ[b,d]フラン-3-イル)メタノン、トリフルオロ酢酸塩、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-4-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-1-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-4-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(1-フェニル-1H-インドール-5-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(5-(トリフルオロメチル)チオフェン-2-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-3-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インダゾール-3-イル)フェニル)メタノン、
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(4-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(2-メチル-1H-インドール-3-イル)フェニル)メタノン、
(4-(1H-インドール-6-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(1H,1’H-[3,4’-ビインドール]-6-イル)メタノン、
[4-(1H-イミダゾール-2-イル)-1-ピペリジル]-[3-(1H-インドール-3-イル)-1H-インドール-6-イル]メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-2-イル)フェニル)メタノン、
(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(3-フェニル-1H-インドール-6-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3-フェニル-1H-インドール-6-イル)メタノン、
(4-((1H-イミダゾール-2-イル)アミノ)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、および
(4-(5-フルオロ-1H-インドール-3-イル)フェニル)(4-(4-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、ならびにそれらの獣医学的に許容される塩からなる群から選択される化合物の、使用。 for preparing a medicament for treating animals with MMVD, CHF, and/or asymptomatic heart failure,
(4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-fluoro-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-indol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-indazol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-phenoxyphenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(phenylamino)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-chloro-[1,1′-biphenyl]-4-yl)methanone, trifluoroacetate,
(4-((1H-imidazol-2-yl)methyl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, trifluoroacetate ,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-5-yl)phenyl)methanone, trifluoroacetate,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(9H-carbazol-2-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(dibenzo[b,d]furan-3-yl)methanone, trifluoroacetate,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-4-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-1-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-4-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(1-phenyl-1H-indol-5-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(5-(trifluoromethyl)thiophen-2-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-3-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indazol-3-yl)phenyl)methanone,
(4-((1H-imidazol-2-yl)methyl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(4-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4-(2-methyl-1H-indol-3-yl)phenyl)methanone,
(4-(1H-indol-6-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(1H,1′H-[3,4′-vindol]-6-yl)methanone,
[4-(1H-imidazol-2-yl)-1-piperidyl]-[3-(1H-indol-3-yl)-1H-indol-6-yl]methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-2-yl)phenyl)methanone,
(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)(3-phenyl-1H-indol-6-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3-phenyl-1H-indol-6-yl)methanone,
(4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and (4-( 5-fluoro-1H-indol-3-yl)phenyl)(4-(4-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone, and veterinary acceptable salts thereof use of a compound selected from the group consisting of
(4-((1H-イミダゾール-2-イル)アミノ)ピペリジン-1-イル)(4’-フルオロ-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-インドール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-インダゾール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-4-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-3-イル)フェニル)メタノン、
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、および
(4-(4-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(2-メチル-1H-インドール-3-イル)フェニル)メタノン、ならびにそれらの獣医学的に許容される塩からなる群から選択される、請求項9に記載の化合物の、使用。 for preparing a medicament for treating animals with MMVD, CHF, and/or asymptomatic heart failure,
(4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-fluoro-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-indol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-indazol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-4-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-3-yl)phenyl)methanone,
(4-((1H-imidazol-2-yl)methyl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and (4-( from 4-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4-(2-methyl-1H-indol-3-yl)phenyl)methanone, and veterinary acceptable salts thereof 10. Use of a compound according to claim 9, selected from the group consisting of:
(4-((1H-イミダゾール-2-イル)アミノ)ピペリジン-1-イル)(4’-フルオロ-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3’-(メチルスルホニル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-インドール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-インダゾール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-((1H-イミダゾール-2-イル)アミノ)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-フェノキシフェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(フェニルアミノ)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3’-クロロ-[1,1’-ビフェニル]-4-イル)メタノン、トリフルオロ酢酸塩、
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、トリフルオロ酢酸塩、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-5-イル)フェニル)メタノン、トリフルオロ酢酸塩、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(9H-カルバゾール-2-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(ジベンゾ[b,d]フラン-3-イル)メタノン、トリフルオロ酢酸塩、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-4-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-1-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-4-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(1-フェニル-1H-インドール-5-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(5-(トリフルオロメチル)チオフェン-2-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-3-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インダゾール-3-イル)フェニル)メタノン、
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(4-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(2-メチル-1H-インドール-3-イル)フェニル)メタノン、
(4-(1H-インドール-6-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(1H,1’H-[3,4’-ビインドール]-6-イル)メタノン、
[4-(1H-イミダゾール-2-イル)-1-ピペリジル]-[3-(1H-インドール-3-イル)-1H-インドール-6-イル]メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-2-イル)フェニル)メタノン、
(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(3-フェニル-1H-インドール-6-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(3-フェニル-1H-インドール-6-イル)メタノン、
(4-((1H-イミダゾール-2-イル)アミノ)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、および
(4-(5-フルオロ-1H-インドール-3-イル)フェニル)(4-(4-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、ならびにそれらの獣医学的に許容される塩からなる群から選択される、有効量の化合物を含む、組成物。 A composition for treating an animal with MMVD, CHF, and/or asymptomatic heart failure, comprising:
(4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-fluoro-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-indol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-indazol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-phenoxyphenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(phenylamino)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-chloro-[1,1′-biphenyl]-4-yl)methanone, trifluoroacetate,
(4-((1H-imidazol-2-yl)methyl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, trifluoroacetate ,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-5-yl)phenyl)methanone, trifluoroacetate,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(9H-carbazol-2-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(dibenzo[b,d]furan-3-yl)methanone, trifluoroacetate,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-4-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-1-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-4-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(1-phenyl-1H-indol-5-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(5-(trifluoromethyl)thiophen-2-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-3-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indazol-3-yl)phenyl)methanone,
(4-((1H-imidazol-2-yl)methyl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(4-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4-(2-methyl-1H-indol-3-yl)phenyl)methanone,
(4-(1H-indol-6-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(1H,1′H-[3,4′-vindol]-6-yl)methanone,
[4-(1H-imidazol-2-yl)-1-piperidyl]-[3-(1H-indol-3-yl)-1H-indol-6-yl]methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-2-yl)phenyl)methanone,
(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)(3-phenyl-1H-indol-6-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(3-phenyl-1H-indol-6-yl)methanone,
(4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and (4-( 5-fluoro-1H-indol-3-yl)phenyl)(4-(4-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone, and veterinary acceptable salts thereof A composition comprising an effective amount of a compound selected from the group consisting of:
(4-((1H-イミダゾール-2-イル)アミノ)ピペリジン-1-イル)(4’-フルオロ-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(トリフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-インドール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-インダゾール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(ベンゾ[d][1,3]ジオキソール-4-イル)フェニル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(1H-インドール-3-イル)フェニル)メタノン、
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、および
(4-(4-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)(4-(2-メチル-1H-インドール-3-イル)フェニル)メタノン、ならびにそれらの獣医学的に許容される塩からなる群から選択される、請求項11に記載の組成物。 The compound is
(4-((1H-imidazol-2-yl)amino)piperidin-1-yl)(4′-fluoro-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-indol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-indazol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(benzo[d][1,3]dioxol-4-yl)phenyl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4-(1H-indol-3-yl)phenyl)methanone,
(4-((1H-imidazol-2-yl)methyl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and (4-( from 4-methyl-1H-imidazol-2-yl)piperidin-1-yl)(4-(2-methyl-1H-indol-3-yl)phenyl)methanone, and veterinary acceptable salts thereof 12. The composition of claim 11, selected from the group consisting of:
(4-(1H-インドール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-インダゾール-3-イル)フェニル)(4-(5-メチル-1H-イミダゾール-2-イル)ピペリジン-1-イル)メタノン、
(4-(1H-イミダゾール-2-イル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、および
(4-((1H-イミダゾール-2-イル)メチル)ピペリジン-1-イル)(4’-(ジフルオロメチル)-[1,1’-ビフェニル]-4-イル)メタノン、ならびにそれらの獣医学的に許容される塩からなる群から選択される、請求項12に記載の組成物。 The compound is
(4-(1H-indol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-indazol-3-yl)phenyl)(4-(5-methyl-1H-imidazol-2-yl)piperidin-1-yl)methanone,
(4-(1H-imidazol-2-yl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and (4-((1H- from imidazol-2-yl)methyl)piperidin-1-yl)(4′-(difluoromethyl)-[1,1′-biphenyl]-4-yl)methanone, and veterinary acceptable salts thereof 13. The composition of claim 12, selected from the group consisting of:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962825051P | 2019-03-28 | 2019-03-28 | |
US62/825,051 | 2019-03-28 | ||
PCT/US2020/024969 WO2020198478A1 (en) | 2019-03-28 | 2020-03-26 | Serotonin 5-ht2b inhibitory compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022527080A JP2022527080A (en) | 2022-05-30 |
JPWO2020198478A5 true JPWO2020198478A5 (en) | 2022-10-25 |
JP7454589B2 JP7454589B2 (en) | 2024-03-22 |
Family
ID=70775466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021557368A Active JP7454589B2 (en) | 2019-03-28 | 2020-03-26 | Serotonin 5-HT2B inhibitory compound |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220162183A1 (en) |
EP (1) | EP3947360A1 (en) |
JP (1) | JP7454589B2 (en) |
CN (1) | CN113631548B (en) |
AU (1) | AU2020245614B2 (en) |
BR (1) | BR112021019314A2 (en) |
CA (1) | CA3134952C (en) |
WO (1) | WO2020198478A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20240781A1 (en) * | 2021-07-26 | 2024-04-17 | Zoetis Services Llc | SEROTONIN 5-HT2B INHIBITOR COMPOUNDS |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0515995D0 (en) | 2005-08-03 | 2005-09-07 | Sandoz Ag | Organic compounds |
KR20080094962A (en) | 2006-02-20 | 2008-10-27 | 아스텔라스세이야쿠 가부시키가이샤 | Amide derivative or salt thereof |
TWI415845B (en) * | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
JP2012512877A (en) | 2008-12-18 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Serotonin 5-HT2B receptor inhibitor |
-
2020
- 2020-03-26 CA CA3134952A patent/CA3134952C/en active Active
- 2020-03-26 CN CN202080024800.0A patent/CN113631548B/en active Active
- 2020-03-26 BR BR112021019314A patent/BR112021019314A2/en unknown
- 2020-03-26 JP JP2021557368A patent/JP7454589B2/en active Active
- 2020-03-26 WO PCT/US2020/024969 patent/WO2020198478A1/en unknown
- 2020-03-26 EP EP20726982.0A patent/EP3947360A1/en active Pending
- 2020-03-26 US US17/441,340 patent/US20220162183A1/en active Pending
- 2020-03-26 AU AU2020245614A patent/AU2020245614B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4544663A (en) | Indolamine derivatives as anti-fertility agents | |
US10220039B2 (en) | Method of treating polycystic kidney diseases with ceramide derivatives | |
KR100681724B1 (en) | Tyrosine kinase inhibitors and pharmaceutical compositions comprising the same | |
RU2006117635A (en) | DERIVATIVES OF INDOLINON AND THEIR APPLICATION FOR TREATMENT OF PATHOLOGICAL CONDITIONS SUCH AS A MALIGNANT NEW FORMATION | |
ES2282495T3 (en) | USE OF INDOLINE AND INDOLINAN DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR FOOD CONSUMPTION REDUCTION. | |
TWI457331B (en) | Enhanced migraine treatments based on ghrelin mimetics | |
RU2011119217A (en) | DERIVATIVES OF PHENETHYLAMIDE AND THEIR HETEROCYCLIC ANALOGUES | |
US11666582B2 (en) | Medicament for treating cough | |
EA000828B1 (en) | Antagonists of gonadotropin releasing hormone | |
JPWO2006022428A1 (en) | Diabetes treatment | |
EP0550083B1 (en) | Medicaments for treating inflammatory conditions or for analgesia containing a NSAID and ranitidine bismuth citrate | |
RU2010122320A (en) | NEW DERIVATIVES 1, 3-DIHYDRO-5-ISOBENZOFURANOCARBONITRIL AND PHARMACEUTICAL COMPOSITION THERE ON THE BASIS FOR TREATMENT OF PREMATURE EJACULATION | |
JPH05509080A (en) | piperidyl-substituted indole | |
JP2922307B2 (en) | Use of indole derivatives as 5HT1 agonists | |
JP2005519056A (en) | Use of a GSK-3β inhibitor in the manufacture of a drug to increase bone formation | |
JPWO2020198478A5 (en) | ||
US20110150834A1 (en) | Crth2 modulators | |
WO2005056012A1 (en) | Indole derivatives for the treatment of bone diseases | |
JPH09500611A (en) | Novel piperidinyl thioindole derivatives, process for their preparation and pharmaceutical compositions containing them, especially useful as analgesics | |
HRP20191532T1 (en) | Imidazolyl-substituted indole derivatives binding 5-ht7 serotonin receptor and pharmaceutical compositions thereof | |
JP3332233B2 (en) | Treatment of addiction through drug and substance abuse | |
JPH0276815A (en) | Medicine | |
RU2008118904A (en) | INDOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR INHIBITORS FOR TREATMENT OF COGNITIVE DISORDERS AND DISORDERS OF SLEEP, OBESITY AND OTHER DISORDERS OF THE CENTRAL NERVOUS SYSTEM | |
KR920700034A (en) | Therapeutic Uses of 5-HT₃Receptor Antagonists | |
AU758983B2 (en) | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation |